Aveos Fleet Performance

Volato Expands Its Volato Go! Flight Program to Texas

Retrieved on: 
Wednesday, October 11, 2023
Automotive, Air, Transport, Transportation, Travel, Fleet Management, Aircraft, Calendar, OPF, PDK, Aveos Fleet Performance, Honda HA-420 HondaJet, Austin–Bergstrom International Airport, Dallas Love Field, HOU, Texas Triangle, OAK, TEB, Daily Deal, VNY, DeKalb–Peachtree Airport, Oakland International Airport, Airline, Volato Aeronaves

network to the Texas Triangle,” said Gary Waldman, Executive Vice President of Fleet Performance at Volato.

Key Points: 
  • network to the Texas Triangle,” said Gary Waldman, Executive Vice President of Fleet Performance at Volato.
  • With Volato Go!, all customers can take advantage of our lowest dynamic market pricing, with the Volato Go!
  • Texas pricing applies to flights between three Texas airports only: DAL (Dallas Love Field), HOU (William P. Hobby Airport) and AUS (Austin-Bergstrom International).
  • Volato’s other solutions include aircraft fractional ownership, the Volato Insider Program, Volato Aircraft Management Services, and ad hoc charter, which includes highly discounted Daily Deals.

Volato Announces Strategic Reorganization to Fuel Sustained Growth and Business Maturity

Retrieved on: 
Thursday, September 14, 2023
Automotive, Air, Transport, Transportation, Travel, Fleet Management, Diamond, Aircraft, Maintenance, PACI, IPO, Commander Fleet Operational Sea Training, University, Marketing, JSX, Aviation, Business, Honda HA-420 HondaJet, Pacific International, Airman, History, WinAir Airlines, XOJET, Aveos Fleet Performance, FAA, US, BDO, Acquisition, JetBlue, Atmosphere of Earth, Royal New Zealand Air Force, Form, CFO, Air force, NetJets, De Beers, Entrepreneurship, Growth, Commercial, Security (finance), NYSE, Proxy, Platinum, Management, Airline, Safety, Superior Air Charter, Volato Aeronaves

"As a rapidly scaling company, it's tempting to focus solely on meeting the immediate demands of growth," said Matt Liotta, Co-Founder and CEO of Volato.

Key Points: 
  • "As a rapidly scaling company, it's tempting to focus solely on meeting the immediate demands of growth," said Matt Liotta, Co-Founder and CEO of Volato.
  • Today’s announcement demonstrates our commitment to evolving our business structure, optimizing operations, and setting new benchmarks for excellence in private aviation."
  • Keith Rabin, who has ably served as CFO of Volato, has been promoted to the role of President.
  • James Cuff, Vice President of Marketing and Business Development at Volato, has 25 years of experience in global consumer brand marketing.

AVEO Oncology to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 5, 2021

Retrieved on: 
Thursday, July 29, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Cars, Motor vehicles, Hatchbacks, Sedans, Subcompact cars, Aveos Fleet Performance, Avianca, Chevrolet Aveo

AVEO Oncology (Nasdaq: AVEO), a commercial and clinical development stage biopharmaceutical company, today announced that it will report second quarter 2021 financial results on Thursday, August 05, 2021.

Key Points: 
  • AVEO Oncology (Nasdaq: AVEO), a commercial and clinical development stage biopharmaceutical company, today announced that it will report second quarter 2021 financial results on Thursday, August 05, 2021.
  • AVEOs management team will host a conference call and audio webcast at 4:30 p.m.
  • ET on Thursday, August 5, 2021, to discuss the financial results and provide a business update.
  • AVEO is a commercial-stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer.

AVEO Oncology to Present at the Jefferies 2021 Virtual Healthcare Conference

Retrieved on: 
Tuesday, May 25, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Life sciences, Biotechnology, Health sciences, Biology, Cancer treatments, Immunology, Aveos Fleet Performance, Avianca, Monoclonal antibody, Biopharmaceutical

AVEO Oncology (Nasdaq: AVEO) today announced that Michael Bailey, president and chief executive officer of AVEO, will present at the Jefferies 2021 Virtual Healthcare Conference on Tuesday, June 1, 2021 at 2:30 p.m. Eastern Time.

Key Points: 
  • AVEO Oncology (Nasdaq: AVEO) today announced that Michael Bailey, president and chief executive officer of AVEO, will present at the Jefferies 2021 Virtual Healthcare Conference on Tuesday, June 1, 2021 at 2:30 p.m. Eastern Time.
  • A live webcast of the presentation can be accessed by visiting the investors section of the Companys website at www.aveooncology.com .
  • AVEO is an oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for cancer patients.
  • AVEOs earlier-stage pipeline includes monoclonal antibodies in oncology development, including AV-203 (anti-ErbB3 mAb) and AV-353 (anti-Notch 3 mAb).

AVEO Announces Proposed Public Offering of Common Stock

Retrieved on: 
Monday, March 22, 2021
Research, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, Cars, Motor vehicles, Stock market, Corporate finance, Hatchbacks, Sedans, Subcompact cars, Aveos Fleet Performance, Chevrolet Aveo, Stock

AVEO Oncology (Nasdaq: AVEO) today announced that it has commenced an underwritten public offering of 5,000,000 shares of its common stock.

Key Points: 
  • AVEO Oncology (Nasdaq: AVEO) today announced that it has commenced an underwritten public offering of 5,000,000 shares of its common stock.
  • In connection with the offering, AVEO intends to grant the underwriters a 30-day option to purchase up to an additional 750,000 shares of its common stock.
  • These forward-looking statements include, among others, statements relating to AVEOs plans to consummate its proposed public offering and the intended use of proceeds therefrom.
  • There can be no assurance that AVEO will be able to complete the proposed public offering on the anticipated terms, or at all.

AVEO Announces Appointment of Mike Ferraresso to Chief Commercial Officer

Retrieved on: 
Wednesday, March 10, 2021
Biotechnology, Pharmaceutical, Health, Oncology, Cars, Chemical compounds, Motor vehicles, Hatchbacks, Sedans, Subcompact cars, Aveos Fleet Performance, Avianca, Chevrolet Aveo, Tivozanib, FOTIVDA® (tivozanib), AVEO Pharmaceuticals, Inc.

AVEO Oncology (Nasdaq:AVEO) today announced the appointment of Mike Ferraresso to chief commercial officer.

Key Points: 
  • AVEO Oncology (Nasdaq:AVEO) today announced the appointment of Mike Ferraresso to chief commercial officer.
  • Mr. Ferraresso will be responsible for managing AVEOs commercial strategy and operations, including the commercialization of FOTIVDA (tivozanib).
  • Directly on the heels of FOTIVDAs approval, it is a pleasure to announce Mikes appointment to chief commercial officer, said Michael Bailey, president and chief executive officer of AVEO.
  • Mr. Ferraresso, who joined AVEO in December 2017, most recently served as senior vice president, business analytics and commercial operations.

AVEO Oncology to Present at the H.C. Wainwright Global Life Sciences Conference

Retrieved on: 
Tuesday, March 2, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Life sciences, Cars, Biotechnology, Health sciences, Hatchbacks, Sedans, Subcompact cars, Aveos Fleet Performance, Avianca, Monoclonal antibody, Chevrolet Aveo, Biopharmaceutical

AVEO Oncology (Nasdaq: AVEO) today announced that Michael Bailey, president and chief executive officer of AVEO, will present at the H.C. Wainwright Global Life Sciences Conference, being held virtually on March 9-10, 2021.

Key Points: 
  • AVEO Oncology (Nasdaq: AVEO) today announced that Michael Bailey, president and chief executive officer of AVEO, will present at the H.C. Wainwright Global Life Sciences Conference, being held virtually on March 9-10, 2021.
  • AVEO is an oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for cancer patients.
  • AVEOs earlier-stage pipeline includes monoclonal antibodies in oncology development, including AV-203 (anti-ErbB3 mAb) and AV-353 (anti-Notch 3 mAb).
  • While AVEO may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.

AVEO Oncology Announces Commitment for an Incremental $10 Million Loan in Addition to Current Tranched, $35 Million Debt Facility with Hercules Capital

Retrieved on: 
Wednesday, January 20, 2021
Oncology, FDA, Health, Clinical trials, Pharmaceutical, Biotechnology, Aveos Fleet Performance, Avianca, Food and Drug Administration, Hercules, System software, Aerospace, Computers

AVEO Oncology (Nasdaq: AVEO) today announced that it has received a commitment letter for an incremental $10 million loan from Hercules Capital, Inc. (NYSE: HTGC, Hercules) and its affiliates, to be added to the current tranched, $35 million debt facility secured with Hercules in August 2020 through an amendment to the amended and restated loan and security agreement (the Loan Agreement).

Key Points: 
  • AVEO Oncology (Nasdaq: AVEO) today announced that it has received a commitment letter for an incremental $10 million loan from Hercules Capital, Inc. (NYSE: HTGC, Hercules) and its affiliates, to be added to the current tranched, $35 million debt facility secured with Hercules in August 2020 through an amendment to the amended and restated loan and security agreement (the Loan Agreement).
  • Under the terms of the Loan Agreement, an initial tranche of $15 million was drawn down at signing.
  • As previously announced, the FDA has assigned AVEOs NDA a Prescription Drug User Fee Act target action date of March 31, 2021.
  • The nonbinding commitment letter is subject to AVEO and Hercules entering into a definitive amendment of the Loan Agreement setting forth the terms of the additional borrowing.

AVEO Oncology Announces Participation at Two Upcoming Investor Conferences

Retrieved on: 
Wednesday, January 6, 2021
Biotechnology, Pharmaceutical, Health, Oncology, Medical specialties, Clinical medicine, Medicine, Immunology, Biotechnology, Immune system, Monoclonal antibody, Aveos Fleet Performance, Mab, GDF15

AVEO is an oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for cancer patients.

Key Points: 
  • AVEO is an oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for cancer patients.
  • AVEOs earlier-stage pipeline includes several monoclonal antibodies in oncology development, including AV-203 (anti-ErbB3 mAb), AV-380 (anti-GDF15 mAb) and AV-353 (anti-Notch 3 mAb).
  • AVEO is committed to creating an environment of diversity and inclusion as a foundation for innovation.
  • While AVEO may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.

AVEO Oncology Announces Webcast of Presentation at the 39th Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Tuesday, January 5, 2021
Biotechnology, Pharmaceutical, Health, Oncology, Cars, Motor vehicles, Aveos Fleet Performance, Avianca, Hatchbacks, Sedans, Subcompact cars, REPLAY, NASDAQ

AVEO Oncology (Nasdaq: AVEO) today announced that Michael Bailey, president and chief executive officer of AVEO, will present at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 5:20 p.m. Eastern Time.

Key Points: 
  • AVEO Oncology (Nasdaq: AVEO) today announced that Michael Bailey, president and chief executive officer of AVEO, will present at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 5:20 p.m. Eastern Time.
  • Following the presentation, Mr. Bailey will be joined by other members of AVEOs management team for a question-and-answer session.
  • A live webcast of the presentation and question-and-answer session can be accessed by visiting the investors section of the Companys website at www.aveooncology.com .
  • A replay of the webcast will be archived for 30 days following the presentation date.